Diabetic
Retinopathy Market, by Disease Type (Proliferative Diabetic Retinopathy and
Non-proliferative Diabetic Retinopathy), by Treatment (Anti Vascular
Endothelial Growth Factor Therapy and Intraocular Steroid Injection), by
Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Geography (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity
Analysis, 2019 - 2027
Diabetic retinopathy is one of
the complications of diabetes, in which blood vessels in the retina gets
damaged due to high blood glucose level. Retina is the light sensitive inner
lining at the back of the eye. Diabetic retinopathy mostly affects both the
eyes. As disease condition progresses, diabetic retinopathy symptoms including
fluctuating vision, blurred vision, impaired color vision or sometimes dark and
empty areas in vision leads to vision loss. The line of treatment for diabetic
retinopathy depending on the disease condition of the patient, may require
laser surgery, intraocular injections, and anti (VEFG) vascular endothelial
growth factor therapy.
Global Diabetic Retinopathy -
Market Dynamics
Increasing incidence of diabetes
along with increasing cases of blindness due to diabetes are expected to drive
the diabetic retinopathy market growth. According to the International Diabetic
Federation report, 2017, around 425 million adults of age group 20 to 79 years
are suffering from diabetes. According to the International Agency for the
Prevention of Blindness, 2016, one in three people having diabetes have high chances
of getting affected by diabetic retinopathy. Moreover, according to the article
published in The Lancet, 2018, the annual incidence of diabetic retinopathy
ranges from 2.2% to 12.7%, globally.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3313
Moreover, several launches and
approvals of new diabetic retinopathy medications are expected to boost growth
of the diabetic retinopathy market over the forecast period. For instance, in
May 2019, Regeneron Pharmaceutical received the U.S. Food and Drug
Administration (FDA) approval for EYLEA, an aflibercept injection for diabetes
retinopathy. EYLEA is the only vascular endothelial growth factor (VEGF)
inhibitor approved in two dosing options for diabetes retinopathy, allowing
doctors to customize treatment as per patient need.
Global Diabetic Retinopathy
Market - Regional Insights
On the basis of geography, the
global diabetes retinopathy market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America accounted
for the largest market share in diabetes retinopathy market, owing to high
prevalence of diabetic retinopathy in the region. According to the National
Health Interview Survey, 2016-17, around 8.6% people have diabetic retinopathy
in the U.S.
Europe also exhibits high growth
in diabetes retinopathy market due to high prevalence of diabetic retinopathy.
According to a report presented by the University of Bonn, 2017, around 17.7%
of diabetic patients have showed signs of moderate non-proliferative diabetic
retinopathy while around 2% patients are affected by severe non-proliferative
diabetic retinopathy in the Europe. Moreover, according to the same source,
around 4.1% of adults aged 45 and above are reported to have vision loss due to
diabetic retinopathy in the Europe.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/diabetic-retinopathy-market-3313
Asia Pacific region is also witnessing
lucrative growth in diabetic retinopathy market due to increasing disposable
income, large patient pool, and innovation in diagnostic approach and
government health insurance policies. According to the journal of Diabetology
report 2018, around 80 million people were suffering from diabetes in Asia
Pacific region in 2017 and is expected to increase to 151 million by 2045.
Furthermore, according to The Union Health Ministry’s first National Diabetes
and Diabetic Retinopathy Survey conducted from 2015-2019, around 16.9% of
people are suffering from diabetic retinopathy in India.
Global Diabetic Retinopathy
Market - Competitive Landscape
Key players operating in the
global diabetic retinopathy market include Novartis AG, Regeneron
Pharmaceuticals, Bayer Healthcare, Actavis Plc, Alimera Science, Pfizer Inc.,
Hoffmann-La Roche Ltd, Abbott Laboratories Ltd, Sirnaomics, Glycadia
pharmaceuticals, Boehringer Ingelheim, Therapeutics Inc, Ampio pharmaceuticals,
Lupin ltd, and others.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3313
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment